Organisation › Details

BioClin Therapeutics Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in the treatment of metastatic bladder cancer. The first clinical study is a Phase 1b/2 study of B-701 in combination with docetaxel. The study includes cohorts in which patients with FGFR3 mutation or fusion will be enrolled; patients will be administered B-701 plus docetaxel, or B-701 alone as monotherapy. The second study is evaluating the combination of B-701 and atezolizumab in mUC patients and will include those with overexpressed FGFR3 as well as those with FGFR3 mutation or fusion in their tumors. B-701 is also being tested in an on-going investigator sponsored study evaluating the combination of B-701 and pembrolizumab in mUC patients. *

 

Period Start 2015-07-23 existent
Period End 2018-11-27 renamed
  Group Rainier Therapeutics Inc.
  Today Rainier Therapeutics Inc.
  Successor Rainier Therapeutics Inc.
Products Industry MAb
  Industry 2 vofatamab (B-701)
Person Person Lau, Stephen (BioClin Therapeutics –201809 Founding CEO STEPPED DOWN 9/18)
     
  Street 130 Market Place
  City 94583 San Ramon, CA
  Tel +1-925-413-6140
    Address record changed: 2017-03-25
     
Basic data Employees n. a.
     
    * Document for �About Section�: BioClin Therapeutics, Inc.. (3/22/17). "Press Release: BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital". San Ramon, CA.
     
   
Record changed: 2019-07-13

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Rainier Therapeutics Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top